Jump to section
Transforming health and lives with the power of genomic prevention.
According to Genomics, genetics is the best predictor of an individual's risk for various diseases. Most of the diseases people experience are preventable if they are identified early. Genomics is a healthcare company that uses large-scale genetic information to estimate patients' risk of developing certain diseases.
This innovative approach to healthcare, called genomic prevention, allows patients to make lifestyle changes and prevent diseases that would otherwise manifest. Not only will this help people live longer, healthier lives but also save NHS resources. Currently being tested with the NHS, the cutting edge technology is leading the way worldwide.
Backers include US life science investment firms F-Prime Capital and Foresite Capital. The funding raised will be used towards Genomics expansion globally as it expands its operations to help treat a much wider range of patients.
Freddie
Company Specialist at Welcome to the Jungle
Jan 2024
$44.7m
LATE VC
Mar 2021
$30m
LATE VC
This company has top investors
Chris Spencer
(Director, Core Analytics)Previously Research Scientist at Wellcome Trust Centre for Human Genetics, University of Oxford for 11 years.
Gil McVean
(Director)Previously Co-Founder at Peptide Groove LLP for 9 years and Professor of Statistical Genetics at University of Oxford for 21 years.
Peter Donnelly
(CEO)Previously Professor of Statistics and Ecology and Evolution at University of Chicago for 1 year and Professor of Statistical Science at University of Oxford for 23 years.